horizon: melflufen plus dexamethasone shows efficacy in r/r myeloma
Published 3 years ago • 62 plays • Length 3:13Download video MP4
Download video MP3
Similar videos
-
4:30
horizon: melflufen dexamethasone in r/r myeloma
-
2:27
subgroup analyses in the horizon trial of melflufen plus dexamethasone in r/r myeloma
-
1:06
long-term outcomes of the ocean study: melflufen is superior to pomalidomide in r/r myeloma
-
4:45
horizon: melflufen & dexamethasone in myeloma
-
5:07
a new horizon: melflufen for r/r multiple myeloma
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
2:23
the significance of variant allele frequency in patients with sf3b1-mutated mds
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
4:56
melflufen for myeloma: horizon
-
8:20
updates on the horizon study: melflufen in r/r multiple myeloma
-
6:19
horizon subgroup analyses: melfufen and dexamethasone in r/r mm
-
2:32
updates on the use of melflufen in r/r multiple myeloma
-
2:09
melflufen in patients with refractory mm: updated analysis of horizon
-
2:40
anchor: melflufen in r/r mm
-
0:45
majestec-2 update: teclistamab plus lenalidomide in r/r multiple myeloma
-
1:02
dreamm-3: safety of belantamab mafodotin versus pom/dex in patients with r/r myeloma
-
4:05
horizon study: emd subgroup analysis
-
2:49
selumetinib plus dexamethasone in r/r all: a phase i/ii trial
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data
-
3:22
anchor: melphalan flufenamide in r/r myeloma
-
2:21
horizon (op-106): melflufen plus dexamethasone